{"nctId":"NCT03923959","briefTitle":"Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population","startDateStruct":{"date":"2020-02-01","type":"ACTUAL"},"conditions":["Hip Fractures"],"count":283,"armGroups":[{"label":"Intervention","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tranexamic Acid Injectable Solution"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Tranexamic Acid Injectable Solution","otherNames":["Cyklokapron"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision of written informed consent\n2. Age \\> or = to 65 years\n3. Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric regions\n4. Indication for one of the following surgical interventions: hemiarthroplasty, total hip replacement, sliding plate and screw fixation, or intramedullary fixation\n\nExclusion Criteria:\n\n1. Indication for closed reduction or percutaneous screw\n2. Allergy to TXA\n3. Cerebrovascular accident/stroke, active coronary disease/myocardial infarction, or deep vein thrombosis/pulmonary emboli within one (1) month of the fracture\n4. Presence of hypercoaguable disorder, including cancer (active disease), elevated blood homocysteine levels, antiphospholipid antibody syndrome and inherited protein deficiencies (antithrombin III, factor V Leiden, protein S \\& C deficiencies, prothrombin gene mutation)","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.","description":"Count of participants with acute post-operative transfusion of packed red blood cells along with the corresponding 95% CI.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Complication Rate","description":"Determine if participants randomized to TXA experienced increased risk of complications compared to placebo. Complications include number of deep vein thrombosis events, pulmonary emboli events, myocardial infarction events, and cerebral vascular events within 12 weeks post hip fracture surgery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Readmission","description":"Determine differences between the groups in 30 day readmission rates.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Rate","description":"Death within 90 days post hip surgery","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Stay","description":"Length of stay immediately post study intervention/surgery for hip fracture","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"4.1"},{"groupId":"OG001","value":"4.8","spread":"3.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":146},"commonTop":["Mild","Moderate"]}}}